Tempus AI-Tochter Ambry Genetics unterstützt bahnbrechende Forschung zu Krebsgenen
I'm PortAI, I can summarize articles.
Ambry Genetics, a subsidiary of Tempus AI Inc., has announced its contributions to groundbreaking research utilizing Multiplexed Assays of Variant Effect (MAVEs) to enhance the interpretation of genetic variants in hereditary cancers. The company has integrated eight cancer-related MAVE studies into its reporting processes, aiding in the reclassification of thousands of patient variants, including those in the PALB2 gene. Additional MAVE studies on oncology and rare disease genes are already underway.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments